MARKET

CERC

CERC

Cerecor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.660
-0.030
-1.12%
After Hours: 2.660 0 0.00% 16:00 07/30 EDT
OPEN
2.680
PREV CLOSE
2.690
HIGH
2.720
LOW
2.640
VOLUME
351.72K
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
1.980
MARKET CAP
253.96M
P/E (TTM)
-2.8247
1D
5D
1M
3M
1Y
5Y
CLSK, SI and EBON among pre market gainers
EyeGate Pharmaceuticals EYEG +127% names Brian Strem CEO, proposes $7M Bayon dealObsEva SA OBSV +28%, Organon ink ebopiprant licensing deal for preterm laborOrbsat Corp. (OSAT) +27%.MOGU Inc. (MOGU) +21%  announces entry into Definitive Agreements
Seekingalpha · 4d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 4d ago
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 4d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 4d ago
34 Stocks Moving in Tuesday's Pre-Market Session
Gainers Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) shares rose 139.7% to $7.48 in pre-market trading after the company announced it entered a non-binding letter of intent to acquire Bayon Therapeutics for roughly $7.1 million.
Benzinga · 4d ago
Cerecor's Crohn's Disease Candidate Shows Encouraging Response In Pretreated Patients
Benzinga · 4d ago
6 Stocks Moving In Monday's After-Hours Session
Gainers Cerecor (NASDAQ: CERC) shares are trading higher after the company announced initial Phase 1b results for CERC-002 in moderate to severe Crohn's Disease patients.
Benzinga · 5d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Eyegate Pharmaceuticals (NASDAQ:EYEG) stock increased by 25.64% to $3.92 during Monday's after-market session. The company's market cap stands at $27.8 million.
Benzinga · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CERC. Analyze the recent business situations of Cerecor through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CERC stock price target is 6.50 with a high estimate of 7.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 89
Institutional Holdings: 60.06M
% Owned: 62.91%
Shares Outstanding: 95.47M
TypeInstitutionsShares
Increased
32
6.86M
New
14
3.65M
Decreased
11
527.81K
Sold Out
6
48.56K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.24%
Key Executives
Chairman/Chief Executive Officer/Director
Michael Cola
Chief Financial Officer/Treasurer
Schond Greenway
Chief Accounting Officer
Christopher Sullivan
Chief Scientific Officer
Garry Neil
Other
Jamie Harrell
Other
H. Jeffrey Wilkins
Lead Director/Independent Director
Suzanne Bruhn
Director
Joseph Miller
Independent Director
Steven Boyd
Independent Director
Phil Gutry
Independent Director
Gilla Kaplan
Independent Director
Magnus Persson
No Data
About CERC
Cerecor, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.

Webull offers kinds of Cerecor Inc stock information, including NASDAQ:CERC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CERC stock methods without spending real money on the virtual paper trading platform.